Get the Stockscreener App
7.45
2.45%
-0.10
Pavmed Inc stock is traded at $7.45, with a volume of 3,772.
It is down -2.45% in the last 24 hours and down -27.36% over the past month.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
See More
Previous Close:
$7.35
Open:
$7.23
24h Volume:
3,772
Relative Volume:
0.18
Market Cap:
$6.45M
Revenue:
$4.03M
Net Income/Loss:
$24.32M
P/E Ratio:
-1.7322
EPS:
-4.3008
Net Cash Flow:
$-45.76M
1W Performance:
+1.27%
1M Performance:
-27.36%
6M Performance:
-59.97%
1Y Performance:
-62.84%
1-Day Range:
$7.00
$7.6299
1-Week Range:
$6.00
$9.255
52-Week Range:
$6.00
$26.85
Pavmed Inc Stock (PAVM) Company Profile
Name
Pavmed Inc
Sector
Industry
Phone
(212) 949-4319
Address
360 MADISON AVENUE, NEW YORK, NY
Compare PAVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
7.00 | 6.77M | 4.03M | 24.32M | -45.76M | -4.3008 |
|
ABT
Abbott Laboratories
|
128.41 | 219.88B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.54 | 141.54B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.37 | 133.39B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.75 | 124.82B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.69 | 48.84B | 5.88B | 1.34B | 799.60M | 2.3489 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-05-20 | Initiated | Ascendiant Capital Markets | Buy |
| Jun-28-18 | Initiated | Maxim Group | Buy |
Pavmed Inc Stock (PAVM) Latest News
PAVmed Announces Reverse Stock Split - citybiz
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 - marketscreener.com
PAVMED announces 1-for-30 reverse stock split - MSN
PAVmed trading halted, news pending - MSN
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
PAVmed stock drops after announcing 1-for-30 reverse split By Investing.com - Investing.com Canada
PAVmed (PAVM) Announces 1-for-30 Reverse Stock Split - GuruFocus
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
PAVmed to implement 1-for-30 reverse stock split in January - Investing.com Nigeria
PAVmed stock drops after announcing 1-for-30 reverse split - Investing.com India
PAVmed to implement 1-for-30 reverse stock split in January By Investing.com - Investing.com South Africa
PAVmed Announces Reverse Stock Split to Maintain Nasdaq Listing - TipRanks
PAVmed announces reverse stock split - marketscreener.com
PAVmed Inc. (NASDAQ:PAVM) Sees Large Drop in Short Interest - Defense World
Here's Why Lucid Diagnostics (LUCD) Declined in Q3 - Finviz
Is PAVmed Inc. stock a buy on dips2025 Technical Overview & Free Fast Gain Swing Trade Alerts - Улправда
Nasdaq Moves: Will PAVmed Inc. stock gain from strong economyEarnings Trend Report & Reliable Price Breakout Alerts - Улправда
Will PAVmed Inc. stock gain from strong economy2025 Price Momentum & Free Low Drawdown Momentum Trade Ideas - Улправда
PAVM FinancialsIncome Statement - Quiver Quantitative
Ascendiant Capital Maintains PAVmed (PAVM) Buy Recommendation - Nasdaq
Ascendiant Capital Lowers Price Target for PAVmed (PAVM) to $17. - GuruFocus
PAVmed stock price target lowered to $17 from $20 at Ascendiant Capital By Investing.com - Investing.com South Africa
PAVmed stock price target lowered to $17 from $20 at Ascendiant Capital - Investing.com
Lucid Diagnostics reports real-world data on esophageal test device By Investing.com - Investing.com Australia
Lucid Diagnostics reports real-world data on esophageal test device - Investing.com
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection - PR Newswire
PAVmed approves reverse stock split amendment - MSN
PAVmed Approves Reverse Stock Split Amendment - The Globe and Mail
Lucid Diagnostics Announces $15.3 Million Registered Direct Offe - GuruFocus
Can PAVmed Inc. stock rebound after recent weaknessMarket Growth Report & Daily Market Momentum Tracking - Newser
Is PAVmed Inc. stock cheap compared to fundamentals2025 Short Interest & Capital Efficiency Focused Ideas - Newser
PAVmed (PAVM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
What drives PAVmed Inc stock priceInflation Impact on Stocks & Control Your Emotions With Discipline Tools - earlytimes.in
Lucid Diagnostics Inc.'s (NASDAQ:LUCD) largest shareholders are individual investors with 38% ownership, public companies own 30% - Yahoo Finance Singapore
Risk Check: Will PAVmed Inc. stock gain from strong economyRecession Risk & Advanced Swing Trade Entry Plans - BỘ NỘI VỤ
Why Being Public Gave PavMed a Competitive Edge - Medical Device and Diagnostic industry
What analysts say about PAVmed Inc stockPrice Channel Trading & Small Investment Capital Tips - earlytimes.in
Pavmed Inc. Reports Q3 2025 Earnings and Strategic Focus - MSN
Will PAVmed Inc. stock benefit from upcoming earnings reports2025 Retail Activity & Low Drawdown Investment Strategies - newser.com
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree - PR Newswire
Will PAVmed Inc. stock deliver strong dividend growthStop Loss & Weekly Top Stock Performers List - newser.com
Is PAVmed Inc. stock ready for breakoutPortfolio Gains Report & Community Driven Trade Alerts - newser.com
Is PAVmed Inc. stock cheap at current valuationJuly 2025 Gainers & Consistent Growth Equity Picks - newser.com
Combining machine learning predictions for PAVmed Inc.July 2025 Analyst Calls & Daily Technical Stock Forecast Reports - newser.com
Pavmed Inc Stock (PAVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):